What is Rheumatoid Arthritis?
Rheumatoid arthritis is an autoimmune disease in which the immune system attacks the synovium, the lining of the joints. It typically causes symmetrical pain and swelling in the small joints of the hands, wrists, and feet, with morning stiffness lasting more than an hour. Early treatment with disease-modifying drugs substantially changes long-term outcomes.
Key takeaways
- Rheumatoid arthritis is systemic — it can affect the lungs, eyes, blood vessels, and heart, not just joints.
- Morning stiffness lasting more than an hour and symmetrical small-joint swelling are the key early clues.
- The first months matter: starting disease-modifying therapy early prevents irreversible joint damage.
- Blood tests such as rheumatoid factor and anti-CCP support the diagnosis but do not make it alone.
- Remission or low disease activity is a realistic treatment goal with modern therapy.
Overview
Rheumatoid arthritis affects roughly 1% of adults and is two to three times more common in women. The immune system mistakenly targets the synovium — the thin membrane lining joints — which thickens, becomes inflamed, and produces enzymes that erode cartilage and bone. Left untreated, this causes joint destruction and deformity within a few years. What makes rheumatoid arthritis different from osteoarthritis is not just the mechanism but the tempo and the whole-body nature: fatigue, low-grade fever, and weight loss are common, and inflammation can affect the lungs, eyes, and blood vessels.
The outlook has changed dramatically over the past two decades. Treating to a target of remission or low disease activity, starting disease-modifying therapy within the first months, and adjusting treatment based on regular measurement have made severe deformity far less common than it once was. The main obstacle now is delay — symptoms are frequently dismissed as ageing or overuse for months before assessment.
What Rheumatoid Arthritis is
In rheumatoid arthritis, autoantibodies — most notably rheumatoid factor and antibodies against citrullinated proteins (anti-CCP) — form, often years before symptoms begin. Immune cells infiltrate the synovium, which proliferates into a destructive tissue called pannus. Inflammatory signals including TNF and interleukin-6 drive the process and also explain the systemic symptoms and the raised cardiovascular risk associated with the disease.
The pattern is characteristically symmetrical and favours the small joints: the knuckles and middle finger joints, the wrists, and the balls of the feet. The joints at the very tips of the fingers are usually spared, which is one of the more reliable ways to distinguish rheumatoid arthritis from osteoarthritis and psoriatic arthritis at the bedside. Larger joints such as knees, shoulders, ankles, and the small joints of the neck can be involved as the disease progresses.
Common symptoms
Symptoms usually develop over weeks to months and include both joint and whole-body features.
- Morning stiffness lasting more than an hour — a hallmark feature
- Symmetrical pain and swelling in the small joints of the hands, wrists, and feet
- Soft, boggy joint swelling rather than the bony enlargement of osteoarthritis
- Persistent fatigue that is out of proportion to activity
- Reduced grip strength and difficulty with buttons, jars, or keys
- Low-grade fever and general malaise during active disease
- Warmth and tenderness over affected joints
Less common symptoms
- Rheumatoid nodules — firm lumps under the skin, often near the elbows
- Dry eyes and dry mouth from associated Sjogren syndrome
- Shortness of breath or dry cough from lung involvement
- Eye redness and pain from scleritis — needs urgent ophthalmology assessment
- Numbness and tingling from nerve compression such as carpal tunnel syndrome
Risk factors
- Female sex — women are affected two to three times more often than men
- Age — onset peaks between 30 and 60, though it can occur at any age
- Smoking — the strongest known environmental risk factor, and it worsens disease severity and treatment response
- Family history — first-degree relatives have higher risk, linked to HLA-DRB1 shared epitope genes
- Obesity — associated with higher risk and lower likelihood of remission
- Periodontal (gum) disease — an association supported by several lines of evidence
- Occupational exposure to silica dust — a recognised environmental contributor
- Prior anti-CCP positivity without symptoms — indicates a pre-clinical phase
Causes
The cause is a combination of genetic susceptibility and environmental triggers. Certain HLA-DRB1 variants change how the immune system presents proteins, making it more likely to react against the body's own citrullinated proteins. Smoking appears to promote that citrullination in the lungs, which is one explanation for its strong association with anti-CCP positive disease.
Once autoimmunity is established, it typically simmers silently for years. Autoantibodies can be detectable long before the first swollen joint, and what tips a person into clinical disease is not fully understood — infection, stress, and hormonal change have all been proposed but none is proven as a trigger.
How it is diagnosed
Diagnosis combines the clinical pattern with blood markers and imaging, and urgency matters because early treatment prevents damage.
| Test or assessment | What it looks at |
|---|---|
| Anti-CCP antibodies | Highly specific for rheumatoid arthritis and often present before symptoms. A positive result also predicts more aggressive disease. |
| Rheumatoid factor | Positive in a majority of patients but also found in other conditions and in some healthy people, so it is supportive rather than definitive. |
| Inflammatory markers (ESR and CRP) | Measure the level of systemic inflammation, used both at diagnosis and to track response to treatment. |
| X-rays of hands and feet | Establish a baseline and can show early erosions or joint space narrowing; often normal at the very beginning. |
| Ultrasound or MRI | More sensitive than X-ray for detecting synovitis and early erosions, useful when the examination is equivocal. |
| Baseline safety panel | Blood count, liver and kidney function, hepatitis and tuberculosis screening — required before starting disease-modifying or biologic therapy. |
Treatment overview
The strategy is to start disease-modifying therapy early and adjust it to reach remission or low disease activity, measured at regular intervals. The categories below describe classes of treatment; selection, combination, and dosing are decided by a rheumatologist.
Conventional synthetic DMARDs
Methotrexate is the usual anchor drug, sometimes with hydroxychloroquine, sulfasalazine, or leflunomide. These slow or halt joint damage rather than only easing pain.
Biologic DMARDs
Injected or infused antibodies targeting TNF, interleukin-6, T-cell co-stimulation, or B cells, used when conventional therapy is not enough.
Targeted synthetic DMARDs
Oral JAK inhibitors, which have specific cardiovascular, clotting, and malignancy warnings that inform who they are suitable for.
Corticosteroids
Used as a short-term bridge while DMARDs take effect, or for flares. Long-term use is minimised because of bone, glucose, and infection effects.
Symptom relief
NSAIDs and analgesics help pain and stiffness but do not slow joint damage, so they never replace disease-modifying therapy.
Physical and occupational therapy
Preserves range of motion and grip function, provides joint protection strategies, and supplies splints or adapted tools.
Cardiovascular and bone risk management
Rheumatoid arthritis independently raises heart disease and osteoporosis risk, so blood pressure, lipids, bone density, and vaccination are part of routine care.
Lifestyle considerations
- Stop smoking — it worsens disease activity and reduces how well treatment works.
- Keep moving: regular low-impact exercise reduces pain and fatigue without worsening inflammation.
- Include strength work to protect joints and preserve muscle, which is lost readily in active disease.
- Balance activity with rest during flares, and use splints or aids rather than pushing through.
- Follow a Mediterranean-style eating pattern; evidence for specific elimination diets is weak.
- Stay current with recommended vaccinations, ideally before starting immunosuppressive therapy.
- Look after teeth and gums — periodontal health is linked to disease activity.
- Report infections early, since many treatments suppress the immune response.
Prevention
- Rheumatoid arthritis cannot currently be prevented, but its risk can be lowered and its damage largely averted.
- Not smoking is the single most effective way to reduce risk, particularly for people with a family history.
- Maintaining a healthy weight lowers risk and improves the chance of remission once diagnosed.
- Good oral and gum health may reduce risk and is worthwhile regardless.
- The most important preventive step after symptoms begin is rapid referral — treatment within the first months prevents irreversible joint damage.
Warning signs and when to get help
Signs that need emergency care
If you believe you are experiencing a medical emergency, call emergency services immediately (911 in the United States).
- A single hot, intensely painful, swollen joint with fever — possible septic arthritis, which is a medical emergency
- Fever, chills, or severe infection while taking immunosuppressive therapy
- Sudden severe eye pain with redness and vision change — possible scleritis
- Sudden breathlessness or chest pain — may reflect lung involvement or a cardiovascular event
- New neck pain with arm or leg weakness or difficulty walking — possible cervical spine instability
Signs that warrant a prompt appointment
These are not emergencies, but they are worth a call to your clinician rather than a wait-and-see.
- A flare of joint swelling and stiffness lasting more than a few days
- New shortness of breath or a persistent dry cough
- Mouth ulcers, unusual bruising, or persistent nausea on methotrexate
- Numbness or tingling in the hands, or new weakness
- Low mood or overwhelming fatigue interfering with daily life
Questions to ask a healthcare professional
Take these to your next appointment — or build an agenda with the Appointment Prep tool.
- Am I seropositive, and what does that mean for my likely disease course?
- What is our treatment target, and how will we measure whether we are reaching it?
- How long before this medicine starts working, and what should I do meanwhile?
- What monitoring blood tests do I need, and how often?
- What infection precautions should I take on this treatment?
- Which vaccines should I have, and is there a best time relative to my medication?
- Should my bone density and cardiovascular risk be assessed?
- What should I do during a flare before I can reach you?
Frequently asked questions
How do I know if my joint pain is rheumatoid arthritis?
Features that raise the possibility include morning stiffness lasting over an hour, symmetrical swelling of the small joints of the hands and feet, and fatigue. Only a clinician can evaluate this, and blood tests plus examination are needed. Prompt assessment matters because early treatment prevents damage.
Can rheumatoid arthritis go into remission?
Yes. With modern treat-to-target therapy, remission or low disease activity is a realistic goal for many people. Remission usually means minimal symptoms and normal inflammatory markers on treatment; medication is typically continued and tapered carefully if at all.
Does diet affect rheumatoid arthritis?
A Mediterranean-style pattern with fish, olive oil, vegetables, and whole grains has modest supporting evidence for symptoms. Claims about specific elimination diets or single foods curing rheumatoid arthritis are not supported. Diet complements but does not replace disease-modifying treatment.
Is rheumatoid arthritis hereditary?
There is a genetic component — first-degree relatives have somewhat higher risk, and certain HLA-DRB1 variants increase susceptibility — but most people with rheumatoid arthritis have no affected relative, and genes alone do not cause it.
Will I end up with deformed joints?
Far less likely than in the past. Severe deformity was common when treatment was delayed or limited to painkillers; with early disease-modifying therapy and regular monitoring, most people avoid significant joint destruction.
Sources
- Arthritis Foundation — Patient guidance on treatment and daily living
- NIAMS — Rheumatoid Arthritis — NIH overview of cause, diagnosis, and therapy
- CDC — Rheumatoid Arthritis — US data and physical activity recommendations
- MedlinePlus — Rheumatoid Arthritis — Consumer summary and medication links
Health Captain links to primary public-health and clinical sources so you can read the original material yourself. See our sources policy.